AP78A - Therapeutic nucleosides - Google Patents

Therapeutic nucleosides Download PDF

Info

Publication number: AP78A
Authority: AP; ARIPO
Prior art keywords: substituted; formula; compound; dideoxyribofuranoside; group
Prior art date: 1987-04-09

Application number

APAP/P/1988/000086A

Other languages

English (en)

Other versions

AP8800086A0 (en

Inventor

George Walter Koszalka

Thomas Anthony Krenitsky

Janet Litster Rideout

Charlene Louise Burns

Original Assignee

The Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-04-09

Filing date

1988-04-08

Publication date

1990-03-12

1987-04-09 Priority claimed from GB878708512A external-priority patent/GB8708512D0/en

1987-05-29 Priority claimed from GB878712691A external-priority patent/GB8712691D0/en

1987-09-30 Priority claimed from GB878723013A external-priority patent/GB8723013D0/en

1988-02-01 Publication of AP8800086A0 publication Critical patent/AP8800086A0/xx

1988-04-08 Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd

1990-03-12 Application granted granted Critical

1990-03-12 Publication of AP78A publication Critical patent/AP78A/en

Links

239000002777 nucleoside Substances 0.000 title description 5
125000003835 nucleoside group Chemical group 0.000 title description 2
230000001225 therapeutic effect Effects 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 61
239000004480 active ingredient Substances 0.000 claims description 45
238000006243 chemical reaction Methods 0.000 claims description 36
-1 cycloalkylthlo Chemical group 0.000 claims description 28
125000000217 alkyl group Chemical group 0.000 claims description 27
229910052739 hydrogen Inorganic materials 0.000 claims description 22
125000003118 aryl group Chemical group 0.000 claims description 17
229910052736 halogen Inorganic materials 0.000 claims description 17
150000002367 halogens Chemical class 0.000 claims description 17
238000011282 treatment Methods 0.000 claims description 17
208000030507 AIDS Diseases 0.000 claims description 13
125000003277 amino group Chemical group 0.000 claims description 13
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
241000725303 Human immunodeficiency virus Species 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
238000011321 prophylaxis Methods 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 10
125000003545 alkoxy group Chemical group 0.000 claims description 9
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 7
125000003710 aryl alkyl group Chemical group 0.000 claims description 7
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 6
125000004659 aryl alkyl thio group Chemical group 0.000 claims description 5
125000000753 cycloalkyl group Chemical group 0.000 claims description 5
125000000623 heterocyclic group Chemical group 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 5
239000002243 precursor Substances 0.000 claims description 5
125000005366 cycloalkylthio group Chemical group 0.000 claims description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
239000005864 Sulphur Substances 0.000 claims description 3
125000004414 alkyl thio group Chemical group 0.000 claims description 3
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
125000005110 aryl thio group Chemical group 0.000 claims description 3
125000004104 aryloxy group Chemical group 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000002883 imidazolyl group Chemical group 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
208000005074 Retroviridae Infections Diseases 0.000 claims description 2
238000013160 medical therapy Methods 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 159
239000000047 product Substances 0.000 description 79
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
239000000203 mixture Substances 0.000 description 49
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 40
238000009472 formulation Methods 0.000 description 38
239000002904 solvent Substances 0.000 description 37
238000004108 freeze drying Methods 0.000 description 35
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 32
239000000741 silica gel Substances 0.000 description 32
229910002027 silica gel Inorganic materials 0.000 description 32
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 25
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 25
101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 25
102000013537 Thymidine Phosphorylase Human genes 0.000 description 25
229920005989 resin Polymers 0.000 description 24
239000011347 resin Substances 0.000 description 24
238000004458 analytical method Methods 0.000 description 22
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 22
239000000706 filtrate Substances 0.000 description 21
239000000725 suspension Substances 0.000 description 21
239000008057 potassium phosphate buffer Substances 0.000 description 20
TZLVRPLSVNESQC-UHFFFAOYSA-N potassium azide Chemical compound [K+].[N-]=[N+]=[N-] TZLVRPLSVNESQC-UHFFFAOYSA-N 0.000 description 19
239000000126 substance Substances 0.000 description 18
239000000243 solution Substances 0.000 description 17
125000001309 chloro group Chemical group Cl* 0.000 description 16
238000006073 displacement reaction Methods 0.000 description 16
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
230000000269 nucleophilic effect Effects 0.000 description 16
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 14
150000003839 salts Chemical class 0.000 description 12
239000003826 tablet Substances 0.000 description 12
150000002148 esters Chemical class 0.000 description 11
239000004615 ingredient Substances 0.000 description 10
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
239000002775 capsule Substances 0.000 description 8
239000008101 lactose Substances 0.000 description 8
229960001375 lactose Drugs 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
229940069328 povidone Drugs 0.000 description 8
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
239000007788 liquid Substances 0.000 description 7
RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
229920001429 chelating resin Polymers 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
239000012312 sodium hydride Substances 0.000 description 6
229910000104 sodium hydride Inorganic materials 0.000 description 6
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 5
206010038997 Retroviral infections Diseases 0.000 description 5
239000002585 base Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
229910052753 mercury Inorganic materials 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
229910000160 potassium phosphate Inorganic materials 0.000 description 4
235000011009 potassium phosphates Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
229940080313 sodium starch Drugs 0.000 description 4
239000007787 solid Substances 0.000 description 4
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
230000036436 anti-hiv Effects 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
NCNOODOWUJWZPD-UHFFFAOYSA-N n-(cyclopropylmethyl)-7h-purin-6-amine Chemical compound N=1C=NC=2N=CNC=2C=1NCC1CC1 NCNOODOWUJWZPD-UHFFFAOYSA-N 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000010257 thawing Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
FBECCZYXHYHVQH-UHFFFAOYSA-N 6-(cyclopropylmethoxy)-7h-purine Chemical compound N=1C=NC=2NC=NC=2C=1OCC1CC1 FBECCZYXHYHVQH-UHFFFAOYSA-N 0.000 description 2
QDZUNLMIDBUULS-UHFFFAOYSA-N 6-butoxy-7h-purine Chemical compound CCCCOC1=NC=NC2=C1NC=N2 QDZUNLMIDBUULS-UHFFFAOYSA-N 0.000 description 2
UAPKUSSHIIMXGE-UHFFFAOYSA-N 6-cyclohexyloxy-7h-purine Chemical compound C1CCCCC1OC1=NC=NC2=C1NC=N2 UAPKUSSHIIMXGE-UHFFFAOYSA-N 0.000 description 2
MPZIWCHLJUGUQQ-UHFFFAOYSA-N 6-cyclopentyloxy-7h-purine Chemical compound C1CCCC1OC1=NC=NC2=C1NC=N2 MPZIWCHLJUGUQQ-UHFFFAOYSA-N 0.000 description 2
MEOMXKNIFWDDGZ-UHFFFAOYSA-N 6-morpholin-4-yl-9h-purine Chemical compound C1COCCN1C1=NC=NC2=C1N=CN2 MEOMXKNIFWDDGZ-UHFFFAOYSA-N 0.000 description 2
IYWUSKBMXQERLH-UHFFFAOYSA-N 6-n-cyclopropyl-7h-purine-2,6-diamine Chemical compound C=12N=CNC2=NC(N)=NC=1NC1CC1 IYWUSKBMXQERLH-UHFFFAOYSA-N 0.000 description 2
WWMYHQCOEFJVFT-UHFFFAOYSA-N 6-propoxy-7h-purin-2-amine Chemical compound CCCOC1=NC(N)=NC2=C1NC=N2 WWMYHQCOEFJVFT-UHFFFAOYSA-N 0.000 description 2
UQQKEKTYLCCYSN-UHFFFAOYSA-N 6-propoxy-7h-purine Chemical compound CCCOC1=NC=NC2=C1NC=N2 UQQKEKTYLCCYSN-UHFFFAOYSA-N 0.000 description 2
IQSRNEOAVVBNGN-UHFFFAOYSA-N 6-pyrrolidin-1-yl-7h-purine Chemical compound C1CCCN1C1=NC=NC2=C1NC=N2 IQSRNEOAVVBNGN-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000012461 cellulose resin Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000011630 iodine Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
238000000465 moulding Methods 0.000 description 2
STYFLCAHEVROJU-UHFFFAOYSA-N n,n-diethyl-7h-purin-6-amine Chemical compound CCN(CC)C1=NC=NC2=C1NC=N2 STYFLCAHEVROJU-UHFFFAOYSA-N 0.000 description 2
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
VMYZUPTWPYPEPE-UHFFFAOYSA-N n-cyclobutyl-7h-purin-6-amine Chemical compound C1CCC1NC1=NC=NC2=C1NC=N2 VMYZUPTWPYPEPE-UHFFFAOYSA-N 0.000 description 2
LMWYJWNGVLKEDL-UHFFFAOYSA-N n-cyclopentyl-7h-purin-6-amine Chemical compound C1CCCC1NC1=NC=NC2=C1NC=N2 LMWYJWNGVLKEDL-UHFFFAOYSA-N 0.000 description 2
ZVXQITNIMKKBBE-UHFFFAOYSA-N n-cyclopropyl-7h-purin-6-amine Chemical compound C1CC1NC1=NC=NC2=C1N=CN2 ZVXQITNIMKKBBE-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
239000002212 purine nucleoside Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 2
229950011457 tiamiprine Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
229960002555 zidovudine Drugs 0.000 description 2
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
QFSMBOBIZVSDLV-UHFFFAOYSA-N 2-(7h-purin-6-ylamino)ethanol Chemical compound OCCNC1=NC=NC2=C1NC=N2 QFSMBOBIZVSDLV-UHFFFAOYSA-N 0.000 description 1
JQMGATKUPCKDEG-UHFFFAOYSA-N 2-Amino-6-(benzylthio)purine Chemical compound C=12NC=NC2=NC(N)=NC=1SCC1=CC=CC=C1 JQMGATKUPCKDEG-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-M 3-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-M 0.000 description 1
BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
ULIQGBPQLPCTAJ-UHFFFAOYSA-N 6-benzylsulfanyl-7h-purine Chemical compound N=1C=NC=2N=CNC=2C=1SCC1=CC=CC=C1 ULIQGBPQLPCTAJ-UHFFFAOYSA-N 0.000 description 1
SFXXRVSPZSOREJ-UHFFFAOYSA-N 6-ethoxy-7h-purin-2-amine Chemical compound CCOC1=NC(N)=NC2=C1NC=N2 SFXXRVSPZSOREJ-UHFFFAOYSA-N 0.000 description 1
BMLKPGJBYUTIHT-UHFFFAOYSA-N 6-ethoxy-7h-purine Chemical compound CCOC1=NC=NC2=C1NC=N2 BMLKPGJBYUTIHT-UHFFFAOYSA-N 0.000 description 1
NIBFSSALYRLHPY-UHFFFAOYSA-N 6-iodo-7h-purine Chemical compound IC1=NC=NC2=C1NC=N2 NIBFSSALYRLHPY-UHFFFAOYSA-N 0.000 description 1
CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
ZAOGIVYOCDXEAK-UHFFFAOYSA-N 6-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=NC2=C1NC=N2 ZAOGIVYOCDXEAK-UHFFFAOYSA-N 0.000 description 1
NXBUZBZGNABKHN-UHFFFAOYSA-N 6-propan-2-yloxy-7h-purine Chemical compound CC(C)OC1=NC=NC2=C1NC=N2 NXBUZBZGNABKHN-UHFFFAOYSA-N 0.000 description 1
102100039725 AH receptor-interacting protein Human genes 0.000 description 1
101710083984 AH receptor-interacting protein Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000713310 Human T-cell lymphotropic virus type 4 Species 0.000 description 1
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033885 Paraparesis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
BQOWUDKEXDCGQS-UHFFFAOYSA-N [CH]1CCCC1 Chemical class [CH]1CCCC1 BQOWUDKEXDCGQS-UHFFFAOYSA-N 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical class N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000006310 cycloalkyl amino group Chemical group 0.000 description 1
KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
125000006317 cyclopropyl amino group Chemical group 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
150000002680 magnesium Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
YEWYVRQMZKOENB-UHFFFAOYSA-N n-cyclohexyl-7h-purin-6-amine Chemical compound C1CCCCC1NC1=NC=NC2=C1NC=N2 YEWYVRQMZKOENB-UHFFFAOYSA-N 0.000 description 1
GSVFENCKYURWTI-UHFFFAOYSA-N n-ethyl-7h-purin-6-amine Chemical compound CCNC1=NC=NC2=C1NC=N2 GSVFENCKYURWTI-UHFFFAOYSA-N 0.000 description 1
PEBFHJTVTOEWIX-UHFFFAOYSA-N n-propan-2-yl-7h-purin-6-amine Chemical compound CC(C)NC1=NC=NC2=C1NC=N2 PEBFHJTVTOEWIX-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
CIAUYDNALIJKPK-UHFFFAOYSA-N n-propyl-7h-purin-6-amine Chemical compound CCCNC1=NC=NC2=C1NC=N2 CIAUYDNALIJKPK-UHFFFAOYSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
LPNBBFKOUUSUDB-UHFFFAOYSA-M p-toluate Chemical compound CC1=CC=C(C([O-])=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-M 0.000 description 1
125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
125000001805 pentosyl group Chemical group 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
SNYDMZJXWYXCKT-UHFFFAOYSA-M sodium propane-1,2,3-triol benzoate Chemical compound [Na+].OCC(O)CO.[O-]C(=O)c1ccccc1 SNYDMZJXWYXCKT-UHFFFAOYSA-M 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
150000003444 succinic acids Chemical class 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
125000005389 trialkylsiloxy group Chemical group 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

APAP/P/1988/000086A 1987-04-09 1988-04-08 Therapeutic nucleosides AP78A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB878708512A GB8708512D0 (en)	1987-04-09	1987-04-09	Therapeutic nucleosides
GB878712691A GB8712691D0 (en)	1987-05-29	1987-05-29	Therapeutic nucleosides
GB878723013A GB8723013D0 (en)	1987-09-30	1987-09-30	Therapeutic nucleosides

Publications (2)

Publication Number	Publication Date
AP8800086A0 AP8800086A0 (en)	1988-02-01
AP78A true AP78A (en)	1990-03-12

Family

ID=27263377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1988/000086A AP78A (en)	1987-04-09	1988-04-08	Therapeutic nucleosides

Country Status (20)

Country	Link
US (1)	US5068320A (cs)
EP (1)	EP0286425B1 (cs)
JP (1)	JP2763888B2 (cs)
KR (1)	KR880012630A (cs)
AP (1)	AP78A (cs)
AT (1)	ATE116984T1 (cs)
AU (1)	AU608590B2 (cs)
CA (1)	CA1326237C (cs)
CS (1)	CS274461B2 (cs)
DE (1)	DE3852710T2 (cs)
DK (1)	DK191688A (cs)
FI (1)	FI87214C (cs)
HU (1)	HU201954B (cs)
IL (1)	IL86007A0 (cs)
MC (1)	MC1915A1 (cs)
NO (1)	NO171641C (cs)
NZ (1)	NZ224189A (cs)
PL (1)	PL154956B1 (cs)
PT (1)	PT87191B (cs)
RU (1)	RU1779256C (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5185437A (en) *	1987-04-09	1993-02-09	Burroughs Wellcome Co.	Therapeutic nucleosides
IL86007A0 (en) *	1987-04-09	1988-09-30	Wellcome Found	6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
US5077280A (en) *	1988-04-12	1991-12-31	Brown University Research Foundation	Treatment of viral infections
IE882585L (en) *	1988-08-25	1990-02-25	Prendergast Patrick T	Viral treatment system
EP0366385B1 (en) *	1988-10-24	1993-06-09	The Wellcome Foundation Limited	Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts
WO1990006312A1 (de) *	1988-11-29	1990-06-14	Institut Für Molekularbiologie Und Analytik (Ima) Gmbh	2', 3'-didesoxyribofuranoside und ein verfahren zu ihrer herstellung
JP2619710B2 (ja) *	1989-02-27	1997-06-11	日本製紙株式会社	２′，３′−ジデオキシプリンヌクレオシド類の製造方法
US5585364A (en) *	1989-04-13	1996-12-17	British Technology Group Limited	Antiviral compounds
US5013829A (en) *	1989-04-26	1991-05-07	University Of Iowa Research Foundation	Stable congener of 2',3'-dideoxyadenosine
DE4020529A1 (de) *	1989-09-12	1991-03-21	Roxana Vasiloiu	Multifunktionelle(s) enzym(e) mit nucleosid-didesoxyribosyltransferase(n) und/oder nucleoside-desoxyribosyltransferasen(n) und/oder kinease- und/oder reduktase- und/oder desaminase- und/oder polymerase-aktivitaet
JPH0637391B2 (ja) *	1989-09-29	1994-05-18	日本製紙株式会社	抗エイズウイルス剤
PT95516A (pt) *	1989-10-06	1991-08-14	Wellcome Found	Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
CA2075490A1 (en) *	1990-02-09	1991-08-10	Hiroaki Mitsuya	6-halo-and 2-amino-6-halo-purine 2',3'-dideoxy nucleosides and their use as antiviral agents
US5654286A (en) *	1993-05-12	1997-08-05	Hostetler; Karl Y.	Nucleotides for topical treatment of psoriasis, and methods for using same
IL143867A0 (en) *	1998-12-23	2002-04-21	Shire Biochem Inc	Antiviral nucleoside analogues
CN101220071B (zh) *	2008-01-17	2011-04-06	南京长澳医药科技有限公司	稳定的6-甲氧基-2’,3’-双脱氧鸟嘌呤核苷及其制备方法和包含它的药物组合物
CN102234280B (zh) *	2010-04-26	2014-01-08	北京大学	D,l-鸟嘌呤核苷类似物及其制备方法和应用
WO2012040127A1 (en)	2010-09-22	2012-03-29	Alios Biopharma, Inc.	Substituted nucleotide analogs
AU2012262021B2 (en) *	2011-06-01	2016-07-28	Janus Biotherapeutics, Inc.	Novel immune system modulators
EP2794630A4 (en)	2011-12-22	2015-04-01	Alios Biopharma Inc	SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
NZ631601A (en)	2012-03-21	2016-06-24	Alios Biopharma Inc	Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en)	2012-03-22	2016-01-29	Alios Biopharma Inc	Pharmaceutical combinations comprising a thionucleotide analog
JP2016513621A (ja) *	2013-03-05	2016-05-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ブルトンチロシンキナーゼの阻害剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0216511A2 (en) *	1985-08-26	1987-04-01	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxycytidine
EP0246497A2 (en) *	1986-05-20	1987-11-25	The Firestone Tire & Rubber Company	Method for manufacturing a first stage radial tire for vehicles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1573777A (en) *	1977-11-03	1980-08-28	Wellcome Found	9-d-arabinonucleosides and an enzymatic process for their preparation
NZ215486A (en) *	1985-03-16	1988-09-29	Wellcome Found	3'-azido-3'-deoxythymidine antiretroviral compositions (zidovudine, azt)
US4724232A (en) *	1985-03-16	1988-02-09	Burroughs Wellcome Co.	Treatment of human viral infections
PT82580B (pt) *	1985-05-15	1989-01-17	Wellcome Found	Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
DK167377B1 (da) *	1985-09-17	1993-10-25	Wellcome Found	3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
ATE108183T1 (de) *	1987-03-24	1994-07-15	Nycomed Imaging As	2',3'-dideoxyribofuranoxid-derivate.
IL86007A0 (en) *	1987-04-09	1988-09-30	Wellcome Found	6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
NZ225447A (en) *	1987-07-20	1991-12-23	Merck & Co Inc	Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions

1988
- 1988-04-07 IL IL86007A patent/IL86007A0/xx unknown
- 1988-04-08 CA CA000563634A patent/CA1326237C/en not_active Expired - Fee Related
- 1988-04-08 MC MC881970A patent/MC1915A1/fr unknown
- 1988-04-08 NZ NZ224189A patent/NZ224189A/xx unknown
- 1988-04-08 PT PT87191A patent/PT87191B/pt active IP Right Grant
- 1988-04-08 KR KR1019880003964A patent/KR880012630A/ko not_active Ceased
- 1988-04-08 FI FI881651A patent/FI87214C/fi not_active IP Right Cessation
- 1988-04-08 PL PL1988271722A patent/PL154956B1/pl unknown
- 1988-04-08 AU AU14444/88A patent/AU608590B2/en not_active Ceased
- 1988-04-08 AT AT88303158T patent/ATE116984T1/de not_active IP Right Cessation
- 1988-04-08 JP JP63087034A patent/JP2763888B2/ja not_active Expired - Lifetime
- 1988-04-08 NO NO881537A patent/NO171641C/no unknown
- 1988-04-08 RU SU884355537A patent/RU1779256C/ru active
- 1988-04-08 HU HU881784A patent/HU201954B/hu not_active IP Right Cessation
- 1988-04-08 CS CS242188A patent/CS274461B2/cs unknown
- 1988-04-08 EP EP88303158A patent/EP0286425B1/en not_active Expired - Lifetime
- 1988-04-08 AP APAP/P/1988/000086A patent/AP78A/en active
- 1988-04-08 DE DE3852710T patent/DE3852710T2/de not_active Expired - Fee Related
- 1988-04-08 DK DK191688A patent/DK191688A/da not_active Application Discontinuation
1989
- 1989-10-06 US US07/417,989 patent/US5068320A/en not_active Expired - Fee Related

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0216511A2 (en) *	1985-08-26	1987-04-01	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxycytidine
EP0246497A2 (en) *	1986-05-20	1987-11-25	The Firestone Tire & Rubber Company	Method for manufacturing a first stage radial tire for vehicles

Also Published As

Publication number	Publication date
DK191688A (da)	1988-10-10
DE3852710D1 (de)	1995-02-23
MC1915A1 (fr)	1989-04-06
NO171641B (no)	1993-01-04
NO881537L (no)	1988-10-10
KR880012630A (ko)	1988-11-28
EP0286425B1 (en)	1995-01-11
PL154956B1 (en)	1991-10-31
RU1779256C (ru)	1992-11-30
CS274461B2 (en)	1991-04-11
FI881651A0 (fi)	1988-04-08
FI87214C (fi)	1992-12-10
CA1326237C (en)	1994-01-18
IL86007A0 (en)	1988-09-30
PT87191B (pt)	1993-02-26
AU1444488A (en)	1988-10-13
US5068320A (en)	1991-11-26
NZ224189A (en)	1991-09-25
JP2763888B2 (ja)	1998-06-11
AU608590B2 (en)	1991-04-11
JPS63267796A (ja)	1988-11-04
NO881537D0 (no)	1988-04-08
PT87191A (pt)	1988-05-01
HUT48269A (en)	1989-05-29
FI87214B (fi)	1992-08-31
EP0286425A3 (en)	1990-12-05
AP8800086A0 (en)	1988-02-01
PL271722A1 (en)	1989-01-23
DE3852710T2 (de)	1995-05-24
NO171641C (no)	1993-04-14
CS242188A2 (en)	1990-09-12
DK191688D0 (da)	1988-04-08
FI881651L (fi)	1988-10-10
HU201954B (en)	1991-01-28
EP0286425A2 (en)	1988-10-12
ATE116984T1 (de)	1995-01-15

Publication	Publication Date	Title
EP0286425B1 (en)	1995-01-11	Therapeutic nucleosides
EP0206497B1 (en)	1994-07-20	Therapeutic nucleosides and their preparation
DK167377B1 (da)	1993-10-25	3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
US5185437A (en)	1993-02-09	Therapeutic nucleosides
EP0199451A2 (en)	1986-10-29	Therapeutic nucleosides
EP0285432B1 (en)	1992-11-11	Therapeutic nucleosides
US5071983A (en)	1991-12-10	Therapeutic nucleosides
AU637831B2 (en)	1993-06-10	Therapeutic necleosides
AU616914B2 (en)	1991-11-14	Therapeutic necleosides
US4920210A (en)	1990-04-24	2,6-diaminopurine-9-β-D-2',3'-dideoxyribofuranoside
US5663154A (en)	1997-09-02	2',3'-dideoxy-3'-fluoro-purine ribonucleosides
EP0306597B1 (en)	1994-11-02	Antiviral nucleosides
AP73A (en)	1990-03-01	Therapeautic nucleosides.
EP0479822B1 (en)	1999-08-18	Therapeutic nucleosides
US5175274A (en)	1992-12-29	Therapeutic nucleosides
WO1988009332A1 (en)	1988-12-01	Therapeutic nucleosides
EP0366287A1 (en)	1990-05-02	Therapeutic nucleosides
CA1336821C (en)	1995-08-29	Therapeutic nucleosides
CA1327005C (en)	1994-02-15	Therapeutic nucleosides
NZ224007A (en)	1991-04-26	3'-azido-3'-deoxythymidine derivatives as antiviral agents
HK1004189A1 (en)	1998-11-20	Antiviral nucleoside combination